U.S., Sept. 13 -- ClinicalTrials.gov registry received information related to the study (NCT07169734) titled 'A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors' on Sept. 10.
Brief Summary: The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic, pharmacodynamic, preliminary anti-tumor activity, and to determine the recommended Phase II dose (RP2D) of the ALE.P03 monotherapy in adult patients with selected squamous solid tumors.
Study Start Date: Aug. 26
Study Type: INTERVENTIONAL
Condition:
Cervical Squamous Cell Carcinoma
Squamous Non-small-cell Lung Cancer
Colorectal Cancer
Intrahepatic Cholangiocarcinoma
Urothelial Carcinoma
Interventi...